Specific Antiviral Therapy of Respiratory Viruses

  • John Oxford
  • Ali Al-Jabri


In this last decade of the twentieth century we inhabit a world of molecules which are being investigated for the first time at the atomic level, while biologists have begun to manipulate them to our advantage. The current scientific literature abounds with descriptions of transgenic animals, of chimaeric viruses, of viral proteins and enzymes analysed by X-ray crystallography, synthetic genes and, most recently, the ability of biologists to manipulate genes even to a point of fusion of the sperm and ovum.


Influenza Virus Respiratory Syncytial Virus Minimum Inhibitory Concen Respiratory Syncytial Virus Infection Respiratory Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Al-Nakib, W., Higgins, P.G., Barrow, G.I., Tyrrell, D.A.J., Andries, K., Vanden Bussche, G. Taylor, N. and Janssen, P.A.J. (1989) Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837) Antimicrob Agents Chemother., 33,522-5.Google Scholar
  2. 2.
    Al-Nakib, W.. Higgins, P.G., Barrow, I., Tyrrell D.A.J., Lenox-Smith I. and Ishitsuka, H. (1987) Intranasal chalcone Ro 09-0410 as prophylaxis against rhinovirus infection in human volunteers. J. Antimicrob. Chemother., 20, 887 - 92.PubMedCrossRefGoogle Scholar
  3. 3.
    Al-Nakib, W., Willman, J., Higgins, P.G., Tyrrell, D.A.J., Shepherd, W.M. and Freestone, D.S. (1987) Failure of intranasally administered 4', 6-dichloroflavan to protect against rhinovirus infection in man. Arch. Virol, 92, 255 - 60.PubMedCrossRefGoogle Scholar
  4. 4.
    Andries, K., Dewindt, B., Brabander, M., Stokbroekx, R. and Janssen, P.A.J. (1988) In vitro activity of R61837, a new antirhinovirus compound. Arch. Virol, 101, 155 - 67.Google Scholar
  5. 5.
    Arden, N.H., Patriarca, P.A., Fasano, M.B., Lui, K.J., Harmon, M.W., Kendal. A.P. and Rimland, D. (1988) The roles of vaccination and amantadine prophylaxis in controlling a outbreak of influenza A (H3N2) in a nursing home. Arch. Intern. Med., 148, 865 - 8.PubMedCrossRefGoogle Scholar
  6. 6.
    Barrow, G.I., Higgins, P.G., Tyrrell, D.A.J, and Andries, K. (1990) An appraisal of the efficacy of the antiviral R61837 in rhinovirus infections in human volunteers. Antiviral Chemistry and Chemotherapy, 1, 279 - 83.Google Scholar
  7. 7.
    Beare, A.S. and Reed, S.E. (1977) The study of antiviral compounds in volunteers, in Chemoprophylaxis and Virus Infections of the Respiratory Tract, vol. 2, (ed. J.S. Oxford ), CRC Press, Cleveland, pp. 27 - 55.Google Scholar
  8. 8.
    Bektimirov, F.A., Douglas, R.G., Dolin, R., Galasso, G.J., Krylov, V.F. and Oxford, J.S. (1985) Current status of amantadine and rimantadine as anti-influenza A agents: memorandum from a WHO meeting. Bull WHO, 63, 51 - 6.Google Scholar
  9. 9.
    Belshe, R.B., Burk, B., Newman, F., Cerruti, R.L. and Sim, I.S. (1989) Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J. Infect. Dis., 159, 430 - 5.PubMedCrossRefGoogle Scholar
  10. 10.
    Brady, M.T., Sears, S.D., Pacini, D.L. et al (1990) Safety and prophylactic efficacy of low dose rimantadine in adults during an influenza A epidemic. Antimicrob. Agents Chemother., 34, 1633 - 6.PubMedGoogle Scholar
  11. 11.
    Bukrinskaya, A.G., Vorkunova, N.K., Kornilayeva, G.V., Narmanbetova, R.A. and Vorkunova G.K. (1982) Influenza virus uncoat-ing in infected cells and effect of rimantadine. J. Gen. Virol, 60, 49 - 59.PubMedCrossRefGoogle Scholar
  12. 12.
    Breese-Hall, C., Dolin, R., Gala, C.L. et al (1987) Children with influenza A infection: treatment with rimantadine. Paediatrics, 80, 275 - 82.Google Scholar
  13. 13.
    Crawford, S.A., Clover, R.D., Abell, T.D., Ramsey, C.N., Glezen, P. and Couch, R.B. (1988) Rimantadine prophylaxis in children: a follow up study. Paediatr. Infect. Dis., 7, 379 - 83.CrossRefGoogle Scholar
  14. 14.
    Cross, P.A. (1991) Current recommendations for the prevention and treatment of influenza in the older population. Drugs & Ageing, 1, 431 - 9.CrossRefGoogle Scholar
  15. 15.
    Davies, J.R., Grilli, E.A., Smith, A.J. and Hoskins, T.W. (1988) Prophylactic use of amantadine in a boarding school outbreak of influenza A. ]. R. Coll Gen. Pract., 38, 346 - 8.Google Scholar
  16. 16.
    Davies, W.L., Grunert, R.R., Haff, R.F. et al (1964) Antiviral activity of 1-adamantanamine (amantadine) Science, 144, 862 - 3.PubMedCrossRefGoogle Scholar
  17. 17.
    Degelau, J., Somani, S.K., Cooper, S.L., Guay, D.R.P. and Crossley, K.B. (1992) Amantadine resistant influenza A in a nursing facility. Arch. Intern. Med., 152, 390 - 3.PubMedCrossRefGoogle Scholar
  18. 18.
    Diana, G.D., Nitz, T.J., Mallamo, J.P. and Treasurywala, A. (1993) Antipicornavirus compounds: use of rational drug design and molecular modelling. Antiviral Chem. Chemother., 4, 1 - 10.Google Scholar
  19. 19.
    Dimmock, N.J. (1982) Initial stages in infection with animal viruses. ]. Gen. Virol, 59, 1 - 22.CrossRefGoogle Scholar
  20. 20.
    Dolin, R., Reichman, R.C., Madore, H.P., Maynard, R., Linton, P.N., and Webber-Jones, J. (1982) A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N. Engl J. Med., 307, 580.Google Scholar
  21. 21.
    Dourmashkin, R.R. and Tyrrell, D.A.J. (1974) Electron microscopic observations on the entry of influenza virus into susceptible cells. J. Gen. Virol, 24, 129 - 41.PubMedCrossRefGoogle Scholar
  22. 22.
    Fleming, D.M. and Cross, K.W. (1993) Respiratory syncytial virus or influenza? Lancet, 342, 1507 - 10.PubMedCrossRefGoogle Scholar
  23. 23.
    Galbraith, A.W., Oxford, J.S., Schild, G.C. and Watson, G.I. (1969) Study of 1-adaman-tanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. Bull WHO, 41, 677 - 82.PubMedGoogle Scholar
  24. 24.
    Galbraith, A.W., Oxford, J.S., Schild, G.C. and Watson, G.I. (1969) Protective effect of 1- adamantanamine hydrochloride against influenza A2 in the family environment. Lancet, ii, 1026.Google Scholar
  25. 25.
    Galbraith, A.W., Oxford, J.S., Schild, G.C. and Watson G.I. (1970) Protective effect of aminoadamantane on influenza A2 infections in the family environment. Ann. N.Y. Acad. Sci., 173, 29 - 43.CrossRefGoogle Scholar
  26. 26.
    HaH, C.B., Dolin, R., Gala, C.L. et al (1987) Children with influenza A infection: treatment with rimantadine. Pediatrics, 80, 275 - 82.Google Scholar
  27. 27.
    Hay, A.J., Kennedy, N.C., Skehel, J.J. and Appleyard, G. (1979) The matrix protein gene determines amantadine-sensitivity of influenza viruses. J. Gen. Virol, 42, 189 - 91.PubMedCrossRefGoogle Scholar
  28. 28.
    Hayden, F.G. and Gwaltney, J.M. Jr ( 1982 ) Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infections. Antimicrob. Agents Chemother., 21, 892 - 7.Google Scholar
  29. 29.
    Hayden, F.G. and Hay, A.J. (1992) Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Topics Microbiol Immunol, 176, 119 - 30.CrossRefGoogle Scholar
  30. 30.
    Hayden, F.G. and Monto, A.S. (1986) Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob. Agents Chemother., 29, 339 - 41.PubMedGoogle Scholar
  31. 31.
    Hayden, F.G., Belshe, R.B., Clover, R.D., Hay, A.J., Oakes, M.G. and Soo, W. (1989) Emergence and apparent transmission of rimantadine resistant influenza A virus in famines. N. Engl J. Med., 321, 1696 - 702.PubMedCrossRefGoogle Scholar
  32. 32.
    Hayden, F.G., Sperber, S.J., Belshe, R.B., Clover, R.D., Hay, A.J. and Pyke, S. (1991) Recovery of drug resistant influenza A virus during therapeutic use of rimantadine. Antimicrob. Agents Chemother, 35, 1741 - 7.PubMedGoogle Scholar
  33. 33.
    Heider, H., Adamczyk, B., Presber, H.W., Schroeder, C., Feldblum, R. and Indulen, M.K. (1981) Occurrence of amantadine and rimantadine resistant influenza A virus strains during the 1980 epidemic. Acta Virologica, 25, 395 - 400.PubMedGoogle Scholar
  34. 34.
    Higgins, P.G., Barrow, G.I., Tyrrell, D.A.J., Isaacs, D. and Gauci, C.L. (1990) The efficacy of intranasal interferon a-2A in respiratory syncytial virus infection in volunteers. Antiviral Res.. 14, 3 - 10.Google Scholar
  35. 35.
    Higgins, P.G., Barrow, G.I., Tyrrell, D.A.J., Snell, N.J.C., Jones, K. and Jolley, W.B. (1991) A study of the efficacy of the immunomodulatory compound 7-thia-8-oxoguanosine in Coronavirus 229E infections in human volunteers. Antiviral Chem. Chemother., 2, 61 - 3.Google Scholar
  36. 36.
    Higgins, P.G., Phillpotts, R.J., Scott, G.M., Wallace, J., Bernhardt, L.L. and Tyrrell, D.A.J. (1983) Intranasal interferon as protection against experimental respiratory Coronavirus infection in volunteers. Antimicrob. Agents Chemother., 24, 713 - 15.PubMedGoogle Scholar
  37. 37.
    Hope-Simpson, E. (1993) The Origin of Epidemic Influenza, Plenum Press, New York.Google Scholar
  38. 38.
    Kubar, O.I., Brjantseva, E.A., Nikitina, L.E. and Zlydnikov, D.M. (1989) The importance of virus drug resistance in the treatment of influenza with rimantadine. Antiviral Res., 11, 313 - 16.PubMedCrossRefGoogle Scholar
  39. 39.
    Levantis, P. and Oxford, J.S. (1992) Molecular aspects of AZT resistance in HIV-I. Res. Virol, 143, 136 - 42.PubMedCrossRefGoogle Scholar
  40. 40.
    Lübeck, M.D., Schulman, J.L. and Palese, P. (1978) Susceptibility of influenza A virus to amantadine is influenced by the gene coding for M protein. J. Virol, 28, 710 - 16.PubMedGoogle Scholar
  41. 41.
    Mast, E.E., Harmon, M.W., Gravenstein, I. et al (1991) Emergence and possible transmission of amantadine resistant viruses during nursing home outbreaks of influenza A (H3N2). Am. J. Epidemiol, 134, 988 - 97.PubMedGoogle Scholar
  42. 42.
    Merrigan, T.C., Reed, S.E., Hall, T.S. and Tyrrell, D.A.J. (1973) Inhibition of respiratory virus infection by locally applied interferon. Lancet, i, 563-7.Google Scholar
  43. 43.
    Monto, A.S. and Arden, N.H. (1992) Implications of viral resistance to amantadine in control of influenza A. Clin. Infect. Dis. 15, 362 - 7.PubMedCrossRefGoogle Scholar
  44. 44.
    Muckenthaler, M., Gunkel. N., Levantis, P. et al. (1992) Sequence analysis of an HIV-I isolate which displays unusually high-level AZT resistance in vitro. J. Med. Virol., 36, 79 - 83.CrossRefGoogle Scholar
  45. 45.
    Nicholson, K.G. and Wiselka, M.J. (1991) Amantadine for influenza A. Br. Med. J., 302, 425 - 6.CrossRefGoogle Scholar
  46. 46.
    Oxford, J.S., Zuckerman, M.A., Race, E., Dourmashkin, R., Broadhurst, K. and Sutton, P.M. (1994) Sodium deoxycholate exerts a direct destructive effect on HIV and influenza viruses in vitro and inhibits retrovirus induced pathology in an animal model. Antiviral. Chem. Chemother., 5, 176 - 181.Google Scholar
  47. 47.
    Oxford, J.S. and Galbraith, A. (1980) Antiviral activity of amantadine: a review of laboratory and clinical data. Pharmacol. Ther., 11, 181 - 262.PubMedCrossRefGoogle Scholar
  48. 48.
    Oxford, J.S. and Oberg, B. (1985) Conquest of Viral Diseases, Elsevier Biomedical Press, Amsterdam.Google Scholar
  49. 49.
    Oxford, J.S. and Potter, C.W. (1973) Amino adamantine resistance strains of influenza A2 virus. J. Hygiene., 71, 227 - 35.CrossRefGoogle Scholar
  50. 50.
    Oxford, J.S., Field, H.J. and Reeves, D.S. (eds) (1986) Drug Resistance in Viruses, other Microbes and Eukaryotes, Academic Press, London.Google Scholar
  51. 51.
    Oxford, J.S., Logan, I.S. and Potter, C.W. (1970) In vivo selection of an influenza A2 strain resistant to amantadine. Nature, 226, 82 - 3.Google Scholar
  52. 52.
    Patriarca, P.A., Kater, N.A., Kendal, A.P., Bregman, D.J., Smith, J.D. and Sikes, R.K. (1984) Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A virus infections in nursing homes. Antimicrob. Agents Chemother., 26, 101 - 3.PubMedGoogle Scholar
  53. 53.
    Philipotts, R.J., DeLong, D.C., Wallace, J., Jones, R.W., Reed, S.E. and Tyrrell, D.A.J. (1981) The activity of enviroxime against rhinovirus infection in man. Lancet, i, 1342-4.Google Scholar
  54. 54.
    Phillpotts, R.J., Higgins, P.G., Willman, J.S. et al. (1984) Intranasal lymphoblastoid interferon (‘Wellferon’) prophylaxis against rhinovirus and influenza virus in volunteers. J. Interferon Res., 4, 535 - 41.PubMedCrossRefGoogle Scholar
  55. 55.
    Phillpotts, R.J., Higgins, P.G., Willman, J.S., Tyrrell, D.A.J, and Lenox-Smith, I. (1984) Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. J. Antimicrob. Chemother., 14, 403 - 9.PubMedCrossRefGoogle Scholar
  56. 56.
    Phillpotts, R.J., Wallace, J., Tyrrell, D.A.J., Freestone, D.S. and Shepherd, W.M. ( 1983 ) Failure of oral 4', 6-dichloroflavan to protect against rhinovirus infection in man. Arch. Virol. 75, 115 - 21.Google Scholar
  57. 57.
    Pinto, L.H., Holsinger, L.J. and Lamb, R.A. (1992) Influenza virus M2 protein has ion channel activity. Cell, 69, 517 - 28.PubMedCrossRefGoogle Scholar
  58. 58.
    Reuman, P.D., Bernstein, D.I., Keefer, M.C., Young, E.C., Sherwood, J.R. and Schiff, G.M. (1989) Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza. Antiviral Res., 11, 27 - 40.PubMedCrossRefGoogle Scholar
  59. 59.
    Schild, G.C. and Sutton, R.N.P. (1965) Inhibition of influenza viruses in vitro and in vivo by 1-adamantanamine hydrochloride. Br. J. Exp. Pathol., 46, 263 - 73.PubMedGoogle Scholar
  60. 60.
    Scott, G.M., Phillpotts, R.J., Wallace, J., Secher, D.S., Cantell, K. and Tyrrell, D.A.J. (1982) Purified interferon as protection against rhinovirus infection. Br. Med.J., 284, 1822 - 5.Google Scholar
  61. 61.
    Scott, G.M., Reed, S., Cartwright, T. and Tyrrell, D.A.J. (1980) Failure of human fibroblast interferon to protect against rhinovirus infection. Arch. Virol., 65, 135 - 9.PubMedCrossRefGoogle Scholar
  62. 62.
    Scott, G.M., Wallace, J., Greiner, J., Phillpotts, R.J., Gauci, C.L. and Tyrrell, D.A.J. (1982) Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet, i, 186 - 8.Google Scholar
  63. 63.
    Sears, S.D. and Clements, M.L. (1987) Protective efficacy of low dose amantadine in adults challenged with wild type influenza A virus. Antimicrob. Agents Chemother., 31, 1470 - 3.PubMedGoogle Scholar
  64. 64.
    Smith, T.J., Kremer, H.J., Luo, M. et al. ( 1986) The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science, 233, 1286 - 93.Google Scholar
  65. 65.
    Stanley, E.D., Muldoon, R.E., Akers, L.W. and Jackson, G.G. (1965) Evaluation of antiviral drugs: the effect of amantadine on influenza volunteers. Ann. N.Y. Acad. Sei., 130, 44 - 51.CrossRefGoogle Scholar
  66. 66.
    Stuart-Harris, C.H., Schild, G.C. and Oxford, J.S. (1985) Influenza: the Viruses and the Disease, Edward Arnold, London.Google Scholar
  67. 67.
    Togo, Y., Hornick, R.B. and Dawkins, A.T. (1968) Studies on induced influenza in man. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against A2/Rockville/l/65 strain. JAMA, 203, 1089 - 91.PubMedCrossRefGoogle Scholar
  68. 68.
    Tyrrell, D.A.J, and Al-Nakib, W. (1988) Prophylaxis and treatment of rhinovirus infections, in Clinical Use of Antiviral Drugs, (ed. E.De Clercq ), Martinus Nijhoff Publishing, The Hague, pp. 241 - 76.Google Scholar
  69. 69.
    Tyrrell, D.A.J, and Oxford, J.S. (1985) Antiviral chemotherapy and interferon. Br. Med. Bull., 41, 307 - 405.Google Scholar
  70. 70.
    Van Voris, L.P., Betts, R.F., Hayden, F.G., Christmas, W.A. and Douglas, R.G. (1981) Successful treatment of naturally occurring influenza A (USSR/77 [H1N1]) JAMA, 245, 1128 - 31.PubMedCrossRefGoogle Scholar
  71. 71.
    Van Voris, L.P. and Newell, P.M. (1992) Antivirals for the chemoprophylaxis and treatment of influenza. Setnin. Respir. Infect., 7, 61 - 70.Google Scholar
  72. 72.
    Von Itzstein, M., Wu, W.Y., Kok, G.B. et al. (1993) Nature, 363, 418 - 23.CrossRefGoogle Scholar
  73. 73.
    Yasin, S.R., Al-Nakib, W. and Tyrrell, D.A.J. (1990) Isolation and preliminary characterisation of chalcone Ro 09-041 0-resistant human rhinovirus type 2. Antiviral Chem. Chemother., 1, 149 - 54.Google Scholar
  74. 74.
    Zhang, A., Nanni, R.G., Li, T. et al (1993) Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14. ]. Mol. Biol, 230, 857 - 67.CrossRefGoogle Scholar
  75. 75.
    Zerial, A., Werner. G.H., Phillpotts, R.J., Willman, J.S., Higgins, P.G. and Tyrrell, D.A.J. (1985) Studies on 44 081 R.P., a new antirhi-novirus compound, in cell cultures and in volunteers. Antimicrob. Agents Chemother., 27, 846 - 50.PubMedGoogle Scholar

Copyright information

© Chapman & Hall 1996

Authors and Affiliations

  • John Oxford
  • Ali Al-Jabri

There are no affiliations available

Personalised recommendations